Biofrontera AG BIFRF

BIFRF Company Overview

Biofrontera AG is a Germany-based biopharmaceutical company focused on the development and commercialization of dermatological therapies and medical products, with a primary emphasis on photodynamic therapy (PDT) for the treatment of certain skin cancers and precancerous lesions. The company operates in the specialty pharmaceuticals and dermatology industries and is best known for its aminolevulinic acid-based drug products used in combination with light-based medical devices. Its core commercial products include Ameluz®, a prescription drug for actinic keratosis and certain forms of non-melanoma skin cancer, and the BF-RhodoLED® lamp platform used during PDT procedures. Revenue is primarily generated through product sales, licensing arrangements, and dermatology-focused commercialization activities.

Biofrontera was founded in 1997 in Germany and evolved from a biotechnology research company into a commercial-stage dermatology-focused pharmaceutical business. Over time, the company expanded through regulatory approvals in Europe and the United States, including approvals from the U.S. Food and Drug Administration and European regulatory authorities for its PDT therapies. Biofrontera has positioned itself within the dermatology market through specialization in field-directed therapies for sun-induced skin damage and physician-administered treatments. The company has also emphasized intellectual property protection surrounding its formulations and light-delivery technologies.